

# MAR 0 1 2012 BY

MAR 06 2002

TECH CENTER 1600/2900

PATENT ATTORNEY DOCKET NO.: 056291-5055

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>ENIE</b>		
In re PA	TENT APPLICATION of:	)
BROW	N et al.	) Group Art Unit: 1624
Appln. 1	No.: 09/762,106	) Examiner: McKenzie, T.
Filed:	February 2, 2001	)
FOR:	AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS	) )
	ssioner of Patents gton, D.C. 20231	·
Sir:		
	AMENDMENT TRANSMITT	AL FORM
	endment responding to the one-month Office Action	•
2. Add:	itional papers enclosed:	
[ [ [	Information Disclosure Statement Form PTO-1449, references included Citations Declaration of Biological Deposit Submission of "Sequence Listing", compute amendment pertaining thereto for biotechnological and/or amino acid sequence.	<del></del>
[	Drawings: Formal Informal (Correct	ction)

Application No.: 09/762,106

Page 2

### 3. Extension of Time

The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136(a) apply.

Applicant believes that no extension of time is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

Applicant petitions for an extension of time, the fees for which are set out in 37 C.F.R. § 1.17(a), for the total number of months checked below:

Total Months Requested	Fee for Extension	[Fee for Small Entity]	
one month two months three months four months	\$ 110.00 \$ 400.00 \$ 920.00 \$ 1,440.00	\$ 55.00 \$ 200.00 \$ 460.00 \$ 720.00	
five months	\$ 1,960.00	\$ 980.00	

If an additional extension of time is required, please consider this a Petition therefor.

An extension for \_\_\_\_\_months has already been secured and the fee paid therefor of \$\_\_\_\_ is deducted from the total fee due for the total months of extension now requested.

Extension of time fee due with this request: \$0.00

### 4. Constructive Petition

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

## 5. Fee Calculation (37 C.F.R. §1.16)

CLAIMS AS AMENDED						
	Claims Remaining After Amendment		Highest No. Previously Paid	Present Extra	at Rate of	Total Fees
Total Claims (37 C.F.R. §1.16(c))	7 .	minus	20	0	x \$18.00 each=	\$ 0.00
Independent Claims (37 C.F.R.§1.16(b))	1	minus	3	0	x \$84 each=	\$ 0.00
[] First presentation of Multiple dependent claim(s) \$280.00					\$ 0.00	
SUB-TOTAL =						\$ 0.00
Fee for Month Extenstion of Time						\$ 0.00
Fee for Information Disclosure Statement						\$ 0.00
Fee for Terminal Disclaimer						\$ 0.00
Reduction by ½ for filing by a small entity						\$ 0.00
TOTAL FEE =						\$ 0.00

### 6. Fee Payment

	No fee is to be paid at this time.
--	------------------------------------

The Commissioner is hereby authorized to charge any additional fees which may be required, including fees due under 37 C.F.R. §§ 1.16 and 1.17, or credit any overpayment to Deposit Account 50-0310.

Respectfully Submitted,

Morgan Lewis & Bockius LLP

Date: March 1, 2002 Morgan Lewis & Bockius LLP Customer No. **009629** 

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Tel. No.: 202-739-3000

DJB:mk

By:

Donald J. Bird

Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001



TECH CENTER 1600/2900

# 6/A 3/11/02 C.Style

ATTORNEY DOCKET NO.: 056291-5055

# MAR 0 1 2002 B

Sir:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:	)
BROWN et al.	) Group Art Unit: 1624
Appln. No.: 09/762,106	) ) Examiner: McKenzie, T
Filed: February 2, 2001	) )
FOR: AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS	) )
Commissioner of Patents Washington, D.C. 20231	

# RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

This is in response to the Office Action dated February 1, 2002 setting forth a restriction requirement. In response to the restriction requirement, applicants hereby elect the invention of Group I, drawn to benzamido compounds, compounds of Formula I with Q=phenyl or naphthalene.

Prior to taking up this application for a first Action on the merits, please amend the claims as follows:

**IN THE CLAIMS:** 

Please cancel claims 4 and 7, without prejudice.

Please amend claim 1 and 8 to read as follows: